Board of Directors
John Glaser, senior vice president at Cerner, is responsible for driving technology and product strategies, interoperability and government policy development. Glaser has devoted his career to furthering health care through innovation. He is committed to helping providers maximize their investment in HIT.
Prior to joining Cerner, Glaser was CEO of the Health Services business unit of Siemens Healthcare, where he was responsible for heading Siemens’ global healthcare IT business. Cerner acquired Siemens Health Services in February 2015.
Formerly, Glaser was vice president and chief information officer at Partners HealthCare, Inc. Previously, he was vice president of information systems at Brigham and Women’s Hospital.
Glaser is a well-respected industry thought leader. He was the founding chair of the College of Healthcare Information Management Executives (CHIME), he’s the past president of the Healthcare Information & Management Systems Society (HIMSS), and has served on numerous boards including the eHealth Initiative, the National Alliance for Health Information Technology, and the American Medical Informatics Association (AMIA).
Additionally, Glaser is a fellow of HIMSS, CHIME, and the American College of Medical Informatics. He is also a former senior advisor to the Office of the National Coordinator for Health Information Technology (ONC).
Glaser has published more than 200 articles and three books on the strategic application of information technology in health care, including the most widely used textbook on the topic: Healthcare Information Systems: A Practical Approach for Health Care Management.
Glaser is on the faculty of the Wharton School at the University of Pennsylvania, the Medical University of South Carolina and the Harvard School of Public Health. He received his PhD in health care information systems from the University of Minnesota.
Mr. Heise leads the activities of the MemorialCare Innovation Fund (MCIF). Over the past 20+ years, Mr. Heise has accumulated a broad range and scope of healthcare experience within both the non-profit and for-profit arenas. His accomplishments include business development and operating experience in entrepreneurial start-up companies, physician organizations, community hospitals and academic medical centers.
Mr. Heise’s experience also includes participation on the Board of Directors for several privately held, venture capital funded companies within the MemorialCare Innovation Fund’s investment portfolio, including Accenx Technologies, Ascender Software, Care Team Connect, Health Care DataWorks, Radianse, and ThromboVision, as well as enjoying board observation rights with Aventura, ForHealth Technologies, MedVentive, MindFrame, PerfectServe and Skylight Healthcare Systems.
Mr. Heise holds a master’s degree in healthcare services administration from the University of Michigan, as well as a Bachelor of Arts in Psychology from Grinnell College.
Joel Krikston is a Managing Director with Merck’s Global Health Innovation Fund, LLC (“GHI”). Joel is focused on identifying new investment opportunities in Health Information Technology and Technology Enabled Solutions with an emphasis on Decision Support, Accountable Care and Population Health. Joel is currently on the Board of MedCPU, Inc., and Aventura, Inc. and is a Board Observer at Electrocore, LLC. Joel also serves as GHI’s representative to the New York Digital Health Accelerator and Health Tech Capital in Silicon Valley, CA.
Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining Merck GHI in 2013, he was an Investment Principal at Johnson & Johnson Development Corporation, leading the group’s efforts in healthcare technology and diagnostics while also supporting medical devices and pharmaceuticals. He has previously served on the Boards of GetWellNetwork (acquired by Welsh Carson in 2012) and Imacor. During Mr. Krikston’s seven years with J&J, he served in a range of business development roles at both the corporate and operating company level focused on the identification, formation, development and launch of new businesses in emergent healthcare segments.
Prior to joining Johnson & Johnson, Joel spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Joel has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University.
Enrico is a pioneer in the life sciences with a history of recognizing and developing new technologies that change markets. He is currently a director of Aventura and Transcend Medical and board observer of AbilTo and OnShift. He previously was an observer at Aventura and Tandem Diabetes (NASDAQ).
Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. At Applied Biosystems, Enrico was one of the major forces behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology.
Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent international speaker. In addition, he is an advisor to several companies in the field of regenerative medicine and molecular diagnostics and is a board observer for Interlace Medical.
Enrico earned his master’s degree in molecular and cell biology from the University of Connecticut.
Sheila is founder and CEO of PatientMatters, a company focused on assisting healthcare in the management of the patient’s obligation. Prior to PatientMatters, she was CEO and Chairman of the Board of Caremedic. Under her leadership Caremedic achieved a lead position in the HCIT revenue cycle market, successfully brought to market the first enterprise class revenue management system, the electronic Financial Record (eFR).
Al Wiegman is Senior Vice President and Managing Director at Safeguard Scientifics (NYSE:SFE), which provides capital to technology-driven businesses in healthcare, financial services and digital media. Al brings more than 15 years of venture capital experience to Safeguard, possessing a successful track record of transactions across the technology and healthcare sectors. Al is currently a board member for Safeguard’s partner companies Aktana, Inc., Aventura, Inc., InfoBionic, Inc. (Chairman) and Zipnosis, Inc.
Prior to joining Safeguard, Al was a General Partner at HLM Venture Partners, a leading venture capital firm, with offices in Boston and San Francisco. At HLM, Al directly participated in 30 early- and growth-stage transactions across the technology and healthcare sectors, and was integrally involved in some notable exits including Madison Dearborn Partners, LLC’s acquisition of Fieldglass, Inc. and Hologic, Inc.’s acquisition of Interlace Medical. Al was also on the board of directors for other HLM portfolio companies including Soteira Inc., Linkwell Health, Inc., Spinal Kinetics, Inc., and Transcend Medical, Inc.
Al began his career as a Senior Financial Analyst at Fleet Bank of New York. He received an M.B.A. from Babson College and a B.A in Economics from Hobart College.
Caleb has nearly 20 years of operating, startup, and financing experience in life science and healthcare companies. He plays an instrumental role in sourcing and structuring deals and works closely with portfolio companies to form strategic partnerships and to develop commercialization and marketing strategies. He currently (or formerly) represents Excel as a Board Director or Observer at AventuraHQ, Molecular Templates, ShapeUp, Saladax Biomedical, Cleveland HeartLab, and MedVentive (sold to McKesson).
Prior to joining Excel, Caleb was a Principal at Biotechonomy, where he financed and managed several entrepreneurial ventures, including Synthetic Genomics, where he was also the Director of Finance, BioTrove (sold to Life Technologies), Biocius (sold to Agilent Technologies), and Xcellerex (sold to GE).
Prior to becoming a venture capitalist, Caleb was an award winning sales and marketing executive at medical device and diagnostics companies. He received his M.B.A. from Babson College, magna cum laude, where he was a Babson Fellow in the Center for Technology Enterprise. He received a B.A. in Biology with a minor in Economics from Colby College.
Aventura CEO & Board Member
A proven visionary with more than 30 years of experience, Patrick has brought his hands-on style of business technology leadership to both small venture-backed organizations and large, global technology firms throughout the country.
Prior to joining Aventura Patrick’s previous leadership positions included Chief Technology Officer for population health management company Phytel, founder of boutique IT consultancy Clear IT Leadership, Chief Technology Officer for Getty Images and Chief Information Officer at PACCAR, Inc.
Are You Prepared for a HIPAA Audit? 7 Steps to Security Readiness
Learn how hospitals have used Sympatica to improve clinical workflow and secure their workstations.
Sign up for a live Sympatica software demo to see it in action!
Want to keep up to date? Get our latest reports, tips and trends delivered right to your inbox.